Envveno Medical Corp (NVNO) — SEC Filings
Envveno Medical Corp (NVNO) — 25 SEC filings. Latest: 8-K (Dec 12, 2025). Includes 12 8-K, 5 10-Q, 3 SC 13G/A.
View Envveno Medical Corp on SEC EDGAR
Overview
Envveno Medical Corp (NVNO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 12, 2025: On December 11, 2025, enVVeno Medical Corp. filed an 8-K report detailing the submission of matters to a vote of security holders and financial statements. The company, formerly known as Hancock Jaffe Laboratories, Inc., is based in Irvine, California.
Sentiment Summary
Across 25 filings, the sentiment breakdown is: 2 bearish, 22 neutral, 1 mixed. The dominant filing sentiment for Envveno Medical Corp is neutral.
Filing Type Overview
Envveno Medical Corp (NVNO) has filed 12 8-K, 2 DEF 14A, 5 10-Q, 1 10-K/A, 3 SC 13G/A, 1 10-K, 1 SC 13G with the SEC between Feb 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (25)
Risk Profile
Risk Assessment: Of NVNO's 21 recent filings, 3 were flagged as high-risk, 8 as medium-risk, and 10 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
Key Executives
- Robert A. Berman
- Matthew M. Jenusaitis
- Director of the Center for Devices and Radiological Health
Industry Context
The medical device market for venous disorders is characterized by a significant unmet need, with millions of patients suffering from Chronic Venous Insufficiency (CVI) in the U.S. Currently, treatment options are limited, particularly for deep venous CVI. enVVeno Medical Corp is aiming to establish a new therapeutic category with its transcatheter venous valve technology, but faces the challenge of defining regulatory pathways in the absence of established industry standards.
Top Tags
financials (7) · 10-Q (5) · 8-K (4) · disclosure (4) · medical-devices (4) · corporate-action (3) · filing (3) · SEC Filing (3) · corporate-governance (2) · Medical Devices (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| SEC File Number | 001-38325 | Identifies the company's filing with the SEC. |
| IRS Employer Identification No. | 33-0936180 | Company's tax identification number. |
| Date of formal appeal request to FDA | 2025-09-18 | Filed for VenoValve supervisory appeal |
| Anticipated FDA appeal decision by | 2025-12-31 | Expected timeline for VenoValve appeal outcome |
| Patients suffering from deep venous CVI in U.S. | 2.5 to 3.5 million | Target market for VenoValve and enVVe |
| Date of Annual Meeting of Stockholders | 2025-12-11 | Virtual meeting at 9:00 AM PST |
| Record Date for voting eligibility | 2025-10-17 | Stockholders of record on this date can vote |
| Shares of Common Stock outstanding | 20,216,176 | As of the Record Date, October 17, 2025 |
| Year Class II Directors' term ends | 2028 | Matthew M. Jenusaitis and Robert A. Berman's term |
| Fiscal year for auditor ratification | 2025 | CBIZ CPAs P.C. appointment for fiscal year ending December 31, 2025 |
| Year of Equity Incentive Plan adoption | 2025 | enVVeno Medical Corporation 2025 Equity Incentive Plan |
| Number of patient and investigator attendees at FDA meeting | 1 | From VenoValve U.S. pivotal study |
| Revenue | $0 | for the three and six months ended June 30, 2025, indicating pre-commercial stage |
| Period End Date | 2025-06-30 | latest reporting period for the 10-Q |
| Prior Year Period End Date | 20240331 | Comparative financial data for Q1 2024 is included. |
Frequently Asked Questions
What are the latest SEC filings for Envveno Medical Corp (NVNO)?
Envveno Medical Corp has 25 recent SEC filings from Feb 2024 to Dec 2025, including 12 8-K, 5 10-Q, 3 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of NVNO filings?
Across 25 filings, the sentiment breakdown is: 2 bearish, 22 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Envveno Medical Corp SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Envveno Medical Corp (NVNO) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Envveno Medical Corp?
Key financial highlights from Envveno Medical Corp's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for NVNO?
The investment thesis for NVNO includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Envveno Medical Corp?
Key executives identified across Envveno Medical Corp's filings include Robert A. Berman, Matthew M. Jenusaitis, Director of the Center for Devices and Radiological Health.
What are the main risk factors for Envveno Medical Corp stock?
Of NVNO's 21 assessed filings, 3 were flagged high-risk, 8 medium-risk, and 10 low-risk.
What are recent predictions and forward guidance from Envveno Medical Corp?
Forward guidance and predictions for Envveno Medical Corp are extracted from SEC filings as they are enriched.